March 22, 2013
New plans will give the body broader scope to assess a medicine’s benefits and costs, rather than just its cost effectiveness
February 01, 2013
Institute says that Roche has ‘censored’ its data, and cannot assess its efficacy and cost correctly
March 01, 2012
NICE has not been asked to change the basis of its assessments "simply to save money," the Institute's chief executive, Sir Andrew Dillon, has said.
PharmaTimes 2013 Copyright | RSS Feed Subscriptions Website by DCSL Software